TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) is now available.
CARsgen Therapeutics Holdings Ltd. has announced a board meeting scheduled for August 14, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. This meeting is a critical step for the company as it evaluates its financial performance and strategizes for future growth, which may influence its market position and stakeholder interests.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$8.96 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. operates in the biotechnology industry, focusing on the development of innovative CAR-T cell therapies for the treatment of cancer. The company is dedicated to advancing its pipeline of products to address unmet medical needs in oncology.
Average Trading Volume: 3,083,616
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.28B
See more insights into 2171 stock on TipRanks’ Stock Analysis page.